CX-546 is the company code given for an ampakine compound by its developer, Cortex Pharmaceuticals. This compound comes right at the heels of cx-516, another ampakine compound that showed much promise as a treatment for ADHD during animal trials, but proved to be disappointing when it was tested on humans. This time around, the studies on cx-546 focused on its potential as a treatment and management for schizophrenia patients. CX-546 was an improvement from cx-516 and initial studies on laboratory animals produced positive results.
Ampakines got its name for its primary mode of action, which is to be positive allosteric modulators of AMPA glutamatergic receptors. Increased receptor activity in the brain is believed to result in the enhancement of the cognitive processes within the brain. It is because of this that cx-546 earned the attention of the online community of nootropic users when its development was first made public.
Cortex Pharmaceutical is well-known for its efforts in developing ampakines for the treatment of neurological and mental conditions like Alzheimer’s disease, Parkinson’s disease, attention deficit hyperactivity disorder (ADHD), schizophrenia, and dementia. It was founded in 1987 and it is currently headquartered in Irvine, CA. Its research into ampakines has in part been done in collaboration with notable international companies like Shire Plc and Servier Laboratories.
Apart from being studied as a treatment for schizophrenia, cx-546 is also being observed in other areas. It is currently still being studied for its ability to reverse the respiratory stress induced by drugs that have sedating effects like barbiturates and opioids. CX-546 is only the third substance known to have this ability with the other two being BW373U86 and BIMU-8.
Just like its predecessor, cx-516, cx-546 showed a lot of promise as a potential treatment for some types of neurological and psychological conditions. One particular area that it has shown strength in is in its ability to encourage antipsychotic reactions in the brain making it a potential treatment for schizophrenia. The advantage of cx-546 over its predecessor as shown in the studies is that it was also observed to have neuroprotective abilities by effecting neuroplasticity on the brain.
The potency of cx-546 as a cognitive enhancer is also suggested to be better than its predecessor because it has the ability to encourage the growth of new neurons to complement its ability to increase glutamic receptor activity. Experienced nootropic users who were able to get their hands on cx-546 report of increased memory retention and recall, and enhanced mental clarity. Some of the users also reported an improved ability to learn new things, a heightened sensory perception, and an improved verbal fluency.
While all these positive reports may seem to point to cx-546 as a better cognitive enhancer than cx-516, the studies on human subjects also proved to be disappointing just like its predecessors. Apparently, this newer ampakine to come out of Cortex Pharmaceutical labs still have the same issues of low bioavailability and short half-life. While the substance is still being used in studies, the focus of these studies no longer focuses on its ability as a cognitive enhancer.
- It is an improvement from cx-516
- It has neuroprotective properties.
- It has shown to have cognitive enhancing abilities.
- It has other medical uses.
- It has a low potency for an ampakine.
- It has poor bioavailability.
- It also has a short half-life just like cx-516
- Its supply is extremely limited.
Due to its poor bioavailability for oral supplementation and low potency, this review will no longer discuss its recommended dosages and usage. Those who are looking for effective ampakines should look towards other types that are proven to be effective, potent, and safe such as sunifiram, unifiram, and IDRA-21.